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Effect of iron treatment on circulating cytokine levels in ESRD
patients receiving recombinant human erythropoietin.
Background. Anemia in patients with end-stage renal disease
(ESRD) is treated with recombinant human erythropoietin
(rhEPO) often in combination with iron. However, iron cata-
lyzes the formation of toxic radicals, which might promote vascu-
lar damage, is a nutrient for microorganisms, and negatively
affects immune pathways, thus increasing the risk for severe
infections.
Methods. We investigated 28 patients on chronic hemodialy-
sis who were randomized to receive either rhEPO alone (N 
15) or rhEPO in combination with intravenous iron (N  13)
for a period of 12 weeks. We analyzed iron therapy associated
changes in cytokine patterns and endogenous radical formation.
Results. Tumor necrosis factor- (TNF-) levels were in-
creased in ESRD patients at study entry and then decreased
significantly over time in subjects receiving additional iron,
while they increased with rhEPO alone. In contrast, we found
serum concentrations of the anti-inflammatory cytokine inter-
leukin (IL)-4 to increase with iron therapy. A significant nega-
tive correlation between iron availability, as determined by trans-
ferrin saturation, and TNF- levels (P  0.008) and a positive
one between transferring saturation and IL-4 (P 0.02) pointed
to the potential role of iron to induce immunologic changes.
Interestingly, iron therapy resulted in a slight decrease in the
amounts of endogenous peroxides, which may be referred to
reduced TNF- concentrations since peroxide concentrations
were positively correlated to TNF- levels (P  0.046) and
negatively to transferrin saturation (P  0.02).
Conclusion. Iron supplementation in ESRD patients down-
regulates proinflammatory immune effector pathways and
stimulates the expression of the anti-inflammatory cytokine
IL-4. Such a condition is detrimental for host response toward
invading pathogens. However, tissue damage by radicals such
as endogenous peroxides may be reduced in this condition due
to impaired TNF- formation.
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Anemia is a frequent clinical condition in patients with
end-stage renal disease (ESRD) and may be primarily
referred to as a hypoproliferative response of erythroid
progenitor cells as a result of accumulation of toxic sub-
stances in the bone marrow, an impaired production of
erythropoietin (EPO), and last, but not least, to a de-
creased availability of iron [1, 2], which is due to distur-
bances of iron homeostasis similar to that observed in
chronic inflammatory disorders [3, 4]. The pathophysiol-
ogy of this diversion of iron metabolism has not been
fully elucidated so far but regulatory effects of cytokines
on iron homeostasis appear to be of pivotal importance.
Anemia in ESRD is treated by subcutaneus or intrave-
nous application of recombinant human erythropoietin
(rhEPO) [5]. However, due to limited availability of iron
the response rates to rhEPO are sometimes not satisfac-
tory and thus iron has to be administered in parallel mostly
intravenously to gain a sufficient increase in hemoglobin
levels [6–8]. However, iron therapy may induce effects
other than anemia correction, which may be associated
with an unfavorable clinical course in ESRD patients.
First, iron influences the immune balance by down-regu-
lating the effectivity of the central T-helper cell type-1
(Th-1) cytokine interferon-gamma (IFN-) toward hu-
man monocytes/macrophages. This leads to impaired for-
mation of nitric oxide, tumor necrosis factor- (TNF-)
or surface expression of major histocompatibility (MHC)
class II antigens by macrophages, thereby weakening
cell-mediated immune response toward invading patho-
gens [9, 10]. Additionally, administration of iron increases
the availability of this essential nutrient for microorgan-
isms and has thus been found to be associated with an
increased incidence of infectious complications in ESRD
patients [11, 12].
On the other hand, iron catalyses the formation of
highly toxic hydroxyl radicals by the Haber-Weiss reac-
tion [13]. Oxygen radical formation and subsequent lipid
peroxidation are postulated to be involved in the patho-
genesis of atherosclerosis [14]. Several epidemiologic
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studies have investigated the role of iron as a potential
risk factor for coronary heart disease. Elevated body
iron stores were associated with an increased risk of coro-
nary heart disease–related death or myocardial infarction
in some [15, 16], but not in all studies [17, 18]. Moreover,
although patients with ESRD appear to be immunocom-
promised, increased levels of proinflammatory cytokines
such as TNF-, [19], IL-1, and IL-6, which may be re-
ferred to the dialysis procedure, have been observed.
[20]. Thus, TNF- may contribute to tissue damage in
ESRD patients in being a potent inducer of radical for-
mation by cells of the reticuloendothelial system [13].
Since no clinical data were available so far on the
effects of iron substitution on immune function and en-
dogenous oxidative stress in ESRD patients, the study
presented herein was initiated.
METHODS
Patients
We investigated a total of 31 patients with ESRD who
underwent regular hemodialysis therapy. All subjects
were on chronic hemodialysis for at least 6 months, re-
ceived 50 to 150 IU rhEPO/kg bodyweight per week,
had serum ferritin levels between 200 and 500 g/L,
and hemoglobin values between 11.5 g/dL and 12.5 g/dL
before entering the study. Patients with signs of acute
infections or inflammation, major comorbid conditions
such as malignancies, recurrent gastrointestinal bleeding,
and clinical signs or symptoms of coronary heart disease
were excluded. The study was approved by the local
ethical committee and written informed consent was ob-
tained from all patients. Prior to study entry, all patients
received rhEPO three times a week (Neorecormon;
Roche, Mannheim, Germany) and, in addition, iron sac-
charate according to serum ferritin levels intravenously.
One week prior to study entry, iron was withdrawn.
Patients were then randomly assigned to receive either
rhEPO and iron (100 mg/week) or rhEPO alone. Patients
were then followed for 3 months and blood samples
for investigation of cytokines and oxidative stress were
drawn at day 0 (study entry), day 7, day 14, day 28, and
day 90 (end of study). None of the patients received a
blood transfusion over the study period. Three patients
did not complete the study. In one case, the patient
retracted the informed consent and two others under-
went renal transplantation.
All patients were dialyzed three times a week for 3
to 5 hours with either a Hemophan dialyser (HG 600,
Gambro, Vienna, Austria) (N  16) or a Polysulfon
dialyzer (F60 or F8, Fresenius, Graz, Austria) (N  12)
using bicarbonate dialysate and a blood flow between 250
mL/min and 350 mL/min. Dialysis prescription remained
unchanged during the study period. Mean Kt/V of the
study group was 1.35 and mean normalized polymerase
chain raction (PCR) was 1.03 with no difference between
the iron/rhEPO or rhEPO group. Iron and rhEpo were
administrated at the end of hemodialysis.
Laboratory determinations
Blood samples were drawn immediately before hemo-
dialysis. Laboratory parameters [e.g., alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
hemoglobin, blood cell count, and iron content] were
examined by routinely used automated laboratory tests,
ferritin concentration by an immunoassay, and trans-
ferrin concentration by a turbitometric method.
Serum specimens were drawn during this routine ex-
amination and stored in aliquots at70C until cytokine
assays were performed. Determinations of serum con-
centrations of TNF-, IL-4, IL-6, IL-10, and IL-12p40
were all carried out by commercially available enzyme-
linked immunosorbent assay (ELISA) kits obtained from
R&D (Minneapolis, MN, USA). The detection limits
were 2 ng/L for TNF-, 5 ng/L for IL-4, 0.7 ng/L for IL-6,
2 ng/L for IL-10, and 2.5 ng/L for IL-12p40, respectively.
For determination of plasma total peroxide concentra-
tions we used the “peroxide activity” assay from Tatzber
KEG (Klosterneuburg, Austria), which is based on the
reaction of horseradish peroxidase with plasma perox-
ides using tetramethylbenzidine as the chromogen sub-
strate. Employing a hydrogen peroxide (H2O2) standard
curve, total peroxide concentrations were calculated and
expressed as micromole H2O2 equivalents per liter plasma.
POX reflects total peroxide concentration in plasma or
serum samples and is thus an indicator for the concentra-
tion of reactive oxygen species in plasma/serum.
Statistical analyses
Analyses were carried out using the statistical software
package SYSTAT 7.01 (SPSS, Inc., Chicago, IL, USA).
Continuous variables were compared according to treat-
ment category by Student t test after Bonferroni correc-
tion for multiple testing. Since immunologic parameters
followed skewed rather than Gaussian distributions, they
were evaluated by nonparametric statistical analysis
(Kruskal-Wallis). This procedure minimizes the possibil-
ity of biasing of results by a few outliers. Trends over
time in cytokine levels, iron status parameters, POX
activity, and other measures according to the experimen-
tal treatment groups were analyzed by repeated measure
analysis of variance (ANOVA). The significances of as-
sociations among various measures were calculated by
Spearman ranks correlation technique.
RESULTS
Among the 28 patients finishing the study 13 received
additional iron therapy, while 15 received rhEPO alone.
Weekly rhEPO dosages were not significantly different
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Table 1. Patients’ baseline characteristics
No iron Additional iron Significance
Parameter (N  15) (N  13) (t test)
Male/female 6/9 5/8 NS
Age years 62.215.4 61.515.3 NS
Epo-dosage U/week 60003000 68403460 NS
Leukocytes n/mm3 72932261 69771929 NS
Erythrocytes 106/mm3 3.920.32 3.850.31 NS
Hemoglobin g/dL 12.50.8 12.30.8 NS
Platelets 103/mm3 22159 19658 NS
Reticulocytes n/1000 34.123.7 31.528.7 NS
Ferritin ng/mL 314129 30283 NS
Transferrin mg/dL 19141 17131 NS
TfS % 21.58.6 24.88.8 NS
Ferroxidase U/L 529.57.2 535.44.3 NS
Haptoglobin mg/dL 12956 12034 NS
LDH U/L 16942 18358 NS
ALT U/L 7.83.4 9.66.3 NS
Predialysis creatinine
mg/dL 9.32.3 9.12.5 NS
Urea mg/dL 14542 14133 NS
TNF- ng/L 6.35.7 8.68.3 NSa
IL-4 ng/L 27.139.2 29.631.5 NSa
IL-6 ng/L 13.611.5 9.85.9 NSa
IL10 ng/L 2.82.8 2.63.7 NS
IL-12p40 ng/L 2.12.1 2.52.8 NSa
Abbreviations are: EPO, erythropoietin; TfS, transferrin saturation; LDH, lactate
dehydrogenase; ALT, alanine aminotransferase; TNF-, tumor necrosis factor-;
IL, interleukin; NS is not significant (P  0.05) as estimated by Student’s t test.
Data are shown as meansS.D.
aComparison of groups by nonparametric Kruskal wallis test
between the two treatment groups at study entry. The
baseline characteristics of all patients are shown in Table
1 and no statistically significant differences were found
among the two groups concerning baseline hematologic
parameters, iron status, or cytokine levels. Nonetheless,
baseline levels for TNF-, IL-4, and IL-6 were increased
in both patient groups (Table 1) as compared to mean
values obtained in healthy volunteers according to the
manufacturer’s instructions corresponding to 	2 ng/L
for TNF-, 	10 ng/L of IL-4, and 	5 ng/L for IL-6,
respectively.
During the treatment period no significant change in
hemoglobin levels over time was observed between the
two treatment groups (Table 2). Moreover, mean weekly
rhEPO concentrations did not change significantly in
either treatment group over the study period of 3 months
(details not shown). When investigating iron status, we
found a significant decrease in ferritin levels in subjects
receiving rhEPO alone, while ferritin concentration pro-
gressively increased when additional iron was given (Ta-
ble 2). In parallel, in the latter group, transferrin satura-
tion significantly increased over time.
When studying the effects of iron treatment on serum
cytokine levels, we found that TNF- concentrations
declined in patients receiving additional iron, while in sub-
jects treated with rhEPO alone, TNF- levels increased and
were significantly higher than in patients receiving addi-
tional iron at the end of the observation period (Fig. 1). In
parallel to TNF-, serum levels of haptoglobin, another
acute phase protein, and IL-6 progressively increased in
patients receiving rhEPO alone (Table 2). In contrast,
serum concentrations of the T-helper cell type-2 (Th-2)–
derived cytokine IL-4 decreased in patients receiving
EPO, while additional application of iron lead to a sig-
nificant increase of IL-4 levels (Table 2).
Endogenous radical formation was estimated by mea-
suring total peroxide activity (POX) [21]. While POX
activity slightly increased over time in the rhEPO treat-
ment group, the opposite was true in patients receiving
additional iron; however, these differences were not sta-
tistically significant (Table 2).
To achieve greater insights toward the interrelation-
ship between iron, immune function, and oxidative stress,
we calculated of Spearman rank correlation coefficients
in either group at the end of treatment. When investigat-
ing patients receiving rhEPO and additional iron ther-
apy, we found a highly significantly positive correlation
between IL-4 and hemoglobin levels, while IL-4 was
negatively associated with TNF- concentrations. In line
with this, we found TNF- to be positively associated
with EPO dosages used in patients, while for IL-4 just
the opposite was true (Table 3). When examining the
interrelationship between iron availability as reflected by
transferrin saturation and cytokines, we found a negative
association between transferrin saturation and TNF-
and a positive one between transferrin saturation and
IL-4 (Fig. 2).
In patients receiving no additional iron treatment,
TNF- concentrations were negatively associated with
hemoglobin levels; however, the associations between cyto-
kines, iron homeostasis, and indicators of erythropoeisis
were less pronounced as compared to patients receiving
additional iron treatment.
When studying correlations between these parameters
and endogenous radical formation, we found in both
groups that POX was positively associated with TNF-
levels and negatively with transferrin saturation (Fig. 3);
however, POX did not correlate to rhEPO dosages or
hemoglobin levels in either group.
DISCUSSION
In the study presented herein, we identified profound
effects of iron therapy on immune function in ESRD
patients receiving rhEPO.
Currently, it is well established that there exist three
CD4
 T-helper cell subsets in humans, termed as naive
T-helper cells, Th-1, Th-2, and Th-3, each of which is
producing a typical set of cytokines that regulate differ-
ent immune effector functions and which crossreact with
each other [22]. Th-1–derived cytokines such as IFN- or
tumor necrosis factor- (TNF-) activate macrophages,
thus contributing to the formation of proinflammatory
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Table 2. Changes in laboratory parameters over time and differences according to iron therapy
ANOVA Differences due
Parameter Therapya Day 1 Day 7 Day 14 Day 28 Day 90 (over time)b to iron therapyc
TNF- ng/L 0 6.35.7 9.49.6 8.18.4 10.78.9 15.49.8 0.05
1 8.68.3 9.16.4 8.06.5 7.15.3 5.23.3 0.02 0.006
IL-10 ng/L 0 2.82.8 3.74.2 3.22.7 3.33.2 5.95.2 0.06
1 2.63.7 3.83.2 2.32.3 2.72.9 2.94.5 0.65 0.26
IL-4 ng/L 0 27.139.2 23.742.3 18.927.1 20.732.7 21.232.1 0.22
1 29.631.5 24.033.8 32.436.7 31.625.4 38.131.4 0.05 0.18
IL-6 ng/L 0 13.111.5 9.25.8 11.09.5 13.29.0 19.211.1 0.08
1 9.85.9 8.25.6 9.87.8 9.48.7 11.110.3 0.27 0.55
IL-12 ng/L 0 2.12.1 1.82.8 1.61.6 1.11.7 2.85.3 0.32
1 2.52.8 2.62.8 2.33.4 1.72.6 2.93.3 0.47 0.53
POX lmol/L 0 7.13.4 6.83.2 7.23.9 7.63.5 7.52.7 0.69
1 6.92.4 6.32.9 6.23.1 6.13.5 6.33.7 0.15 0.27
Reti n/1000 0 34.123.7 32.019.3 31.720.0 28.418.6 33.221.9 0.52
1 31.528.7 33.035.7 28.124.7 32.226.3 28.728.0 0.23 0.12
Ferritin lg/L 0 314129 293128 259138 290162 16097 	0.001
1 30283 32586 366115 484206 556282 	0.001 	0.001
TfS % 0 21.58.6 21.610.3 20.510.4 20.112.0 18.410.2 0.38
1 24.88.8 23.410.4 23.57.4 26.07.3 38.119.9 0.01 0.08
Haptoglobin 0 12956 13767 13864 16268 16375 0.025
1 12034 12436 13872 14379 13053 0.84 0.36
LDH 0 16942 15839 15238 17242 18842 0.02
1 18358 18239 18151 18341 18635 0.76 0.6
Creatinine 0 9.32.3 9.42.5 9.62.3 9.62.7 10.02.3 0.23
1 9.12.5 9.42.7 9.52.6 9.82.7 9.82.8 0.25 0.77
Hemoglobin 0 12.40.8 12.30.8 12.20.7 12.00.8 12.10.8 0.36
1 12.30.8 12.10.9 12.10.7 12.00.7 12.51.2 0.28 0.1
Abbreviations are: TNF-, tumor necrosis factor-; IL, interleukin; POX, peroxide activity; Reti, reticulocytes; TfS, transferrin saturation; LDH, lactate dehydrogenase.
a Therapy: 0, no additional iron; 1, additional iron
b Trends over time in the respective treatment group as estimated by ANOVA analysis of variance, P values are shown
c Significances of differences in trends over time between the two treatment groups
Fig. 1. Changes in tumor necrosis factor- (TNF-) levels in end-stage
renal disease (ESRD) patients as a function of iron therapy. ESRD
patients were treated with recombinant human erythropoietin (rhEPO)
for correction of renal anemia and were then randomly assigned to
receive either additional iron or not over a period of 3 months. Day 1 was
at study entry and day 90 was the end of study. TNF-was determined in
patients’ sera as outlined in the Methods section. *P 0.017, difference
in circulating TNF- levels between the two groups at day 90 as esti-
mated by nonparametric Kruskal-Wallis test; #P  0.006, differences
in trends over time between the two treatment groups (additional iron
versus none) as estimated by analysis of variance (ANOVA) analysis.
cytokines, such as TNF-, IL-1, or IL-6, and the induc-
tion of cytotoxic immune effector mechanisms of macro-
phages. By contrast, Th-2 cells produce IL-4, IL-5, IL-9,
and IL-13, which, in part, exert anti-inflammatory actions
via inhibition of various macrophage functions [23].
Herein, we found that iron supplementation was asso-
ciated with reduced endogenous TNF- levels in patients
with ESRD at study end. This may be referred to the
inhibitory effect of iron toward IFN- activity, which
leads to impaired expression of IFN-–inducible genes
in monocytes/macrophages, such as TNF- or nitric ox-
ide in vitro and in vivo [10, 24–26]. In a line with this,
we also found that the concentrations of the anti-inflam-
matory Th-2–derived cytokine IL-4 levels increased with
iron therapy [27].
Nonetheless, significances in immune and iron param-
eters between the two groups were most pronounced at
the end of the study; however, significant difference in
trends (e.g., TNF- levels were observed even after 4
weeks) (P 0.03). This may relate to the fact that dialysis
patients are in a chronic inflammatory state and since
considerable amounts of iron were present at study entry
in both groups. Therefore, it appears reasonable that a
prolonged period of time is needed to see iron therapy–
mediated differences on immune function or iron ho-
meostasis.
According to the Th-1/Th-2 paradigm [22, 23], this
observation may refer to iron-mediated impairment of
IFN- activity, which derepresses the inhibitory effects
of this cytokine toward Th-2 cell activity, thus leading
to increased formation and release of circulating IL-4
upon iron supplementation. This fits nicely to our obser-
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Table 3. Spearman rank correlations at the end of therapy in the respective subgroups and in all patients (day 90)
Transferrin
Hemoglobin TNF- IL-4 Ferritin EPOa saturation
Patients receiving additional iron therapy
TNF- 0.17 —
IL-4 0.76b 0.51b —
Ferritin 0.06 0.31 0.21 —
EPOa 0.35 0.43 0.74 0.49 —
Transferrin saturation 0.29 0.54b 0.52b 0.40 0.54b
POX 0.06 0.31 0.17 0.24 0.16 0.37
Patients receiving no iron therapy
TNF- 0.52b —
IL-4 0.09 0.18 —
Ferritin 0.20 0.19 0.04 —
EPOa 0.28 0.53b 0.25 0.24 —
Transferrin saturation 0.38 0.14 0.03 0.71b 0.47b —
POX 0.08 0.45b 0.12 0.41 0.23 0.51b
Abbreviations are: TNF-, tumor necrosis factor-; IL, interleukin; EPO, erythropoietin; POX, peroxidase activity.
Spearman rank correlation co-efficients are shown.
a EPO, weekly therapeutic EPO dosage at the end of the study period (day 90)
b P 	 0.05 after Bonferroni correction.
Fig. 2. Association between iron status and cytokine levels in end-stage
renal disease (ESRD) patients. (A ) Correlation between transferrin satu-
ration (TfS) as a marker for iron availability and tumor necrosis factor-
(TNF-) levels in ESRD patients at the end of the study period (r,
correlation coefficient; P, significance value following Bonferroni cor-
rection). The regression line and the 95% CI are shown. (B ) Association
between transferrin saturation and circulating levels of the anti-inflam-
matory cytokine interleukin-4 (IL-4) at the end of the study period.
vation of a negative association between IL-4 and TNF-
in the iron treatment group, the contrasting correlations
of transferrin saturation with IL-4 and TNF-, and, fi-
nally, to data obtained in infection models where iron
supplementation or overload led to a shift from Th-1 to
Th-2 immune function [24–28].
Most interestingly, in our study, iron supplementation
rather decreased endogenous radical formation, as moni-
tored by determination of POX activity. Based on the
results of the Spearman rank correlations demonstrating
a positive association between TNF- and POX and a
negative one between transferrin saturation and POX,
one may speculate that iron therapy may limit peroxide
formation by inhibiting the production of its main in-
ducer, TNF- [13].
However, we can not rule out that iron may induce
oxidative stress by pathways not being under the control
for TNF- such as lipid peroxidation, thereby causing
Fig. 3. Associations between radical formation and immune status in
end-stage renal disease (ESRD) patients under recombinant human
erythropoietin (rhEPO) therapy. (A ) Correlation between tumor ne-
crosis factor- (TNF-) and peroxidase activity (POX) in ESRD pa-
tients at the end of the study period (r, correlation coefficient; P, signifi-
cance value following Bonferroni correction). The regression line and
the 95% CI are shown. (B ) Association between transferrin saturation
(TfS) and POX .
tissue damage [29, 30] or if the lack of increased POX
formation in iron-treated patients may be referred to
induction of ferritin synthesis by iron therapy with subse-
quent incorporation and detoxification of the metal
within the ferritin core protein.
Nonetheless, this leads to the questions of whether or
not the effects of iron on immunity may be beneficial or
detrimental to ESRD patients. On the one hand, reduced
TNF- activity decreases cytokine-induced oxidative
stress and possibly reduces the risk of cardiac events in
ESRD patients [31]. On the other hand, iron-mediated
weakening of the Th-1 immune effector branch with a
subsequent strengthening of Th-2–mediated immune ef-
fector function is an unfavorable condition in the case of
an acute infection or tumor disease apart from the fact
that increased iron availability may enhance the growth
of invading pathogens and malignant tissues [12, 32].
This is especially relevant in ESRD patients since im-
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mune effector function in these subjects is already im-
paired, which has partly been referred to the antiprolifer-
ative effects of accumulating toxic substances and the
continuous immune activation upon exposure of circulat-
ing blood to dialysate membranes [19, 20].
Thus, it will be mandatory to design prospective stud-
ied to get more insights toward long-lasting clinical ef-
fects of iron supplementation and subsequent immune
modulation in ESRD patients.
Nonetheless, the interactions of iron with cytokines
may also have important implications for the pathophysi-
ology and therapy in renal anemia.
The positive association between IL-4 and hemoglobin
levels found in patients receiving additional iron may
thus result from at least two factors: (1) iron may dimin-
ished TNF- formation and reduce the antiproliferative
effects exerted by this cytokines toward erythroid pro-
genitor cells [3], an action which may be supported by
increased levels of the anti-inflammatory cytokine IL-4;
and (2) iron supplementation may overcome the limited
availability of the metal toward erythroid progenitor cells
thus stimulating erythropoiesis [7, 8]. The hypothesis
that IL-4 may be beneficial in renal anemia is further
supported by the finding of reduced EPO dosages
needed in patients with high IL-4 levels (Table 3), while
subjects with increased circulating TNF- concentrations
needed more EPO for correction of anemia, which is in
good accordance with previous data [33, 34].
A limitation of our study arises from the fact that, due
to ethical reasons and in order to avoid an additional
biasing of the results by application of blood transfusions,
our patients were only moderately anemic and iron stores
were well filled up at study entry. Thus, it will be relevant
to see which effects iron supplementation may have on
immune regulation when patients are more anemic
and/or when iron stores (as estimated by ferritin levels)
and iron availability (as reflected by transferrin satura-
tion) are reduced. Nonetheless, from this, it also is evi-
dent that continuous monitoring of iron status is an es-
sential clinical investigation in ESRD patients being
aware of the fact that the amount of circulating iron is
of pivotal importance for erythropoiesis, immunosurveil-
lance, and toxicity. For this aim, it would be beneficial
to determine the amount of metabolically available iron
(i.e., iron not bound to ferritin or transferrin), which
may exert the biologic effects of the metal toward immu-
nity and radical formation, in ESRD patients according
to a fluorescence-based method [35] to have a better
clinical monitor for iron traffic in ESRD patients.
Thus, future prospective investigations are warranted
to determine the optimal concentration of iron given
therapeutically to ESRD patients in order to achieve opti-
mal results in terms of anemia correction and to minimize
the detrimental effects of the metal in terms of cardiovas-
cular toxicity and infectious complications partly linked
to immunodepression.
CONCLUSION
We found that iron therapy has profound effects on
immune function by inhibiting TNF- production and
increasing Th-2 activity via IL-4 formation. This may
have important implications on the susceptibility toward
infections, the risk for cardiac events, and the degree of
anemia in ESRD patients.
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